MaxCyte, Inc. Block Listing Return (1158D)
March 01 2022 - 2:01AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 1158D
MaxCyte, Inc.
01 March 2022
MaxCyte, Inc.
("MaxCyte" or the "Company")
Block Listing Return
Gaithersburg, Maryland - 1 March 2022: MaxCyte, Inc. (Nasdaq:
MXCT; LSE: MXCT), a leading provider of enabling platform
technologies for ex-vivo cell engineering, makes the following
notification pursuant to AIM Rule 29 and Schedule Six of the AIM
Rules for Companies, regarding its existing block listings:
Name of applicant: MaxCyte, Inc.
Name of scheme: MaxCyte Long Term Incentive Plan
-------------------------------------------------------------
Period of return: From: 1 September 2021 To: 28 February 2022
---------------------- -------------------------- ------ -------------------------
Balance of unallotted securities under scheme(s) from 78,658 ordinary shares of common stock of $0.01 each
previous return:
-------------------------------------------------------------
Plus: The amount by which the block scheme(s) has been 13,000,000 ordinary shares of common stock of $0.01 each
increased since the date of the last
return (if any increase has been applied for):
-------------------------------------------------------------
Less: Number of securities issued/allotted under 901,574 ordinary shares of common stock of $0.01 each
scheme(s) during period (see LR3.5.7G):
-------------------------------------------------------------
Name of contact: Amanda Murphy, Chief Financial Officer
Ron Holtz, Chief Accounting Officer
Telephone number of contact: +1 301 944 1660
---------------------------------------
For further information, please contact: +1 415-937-5400
MaxCyte Contacts: ir@maxcyte.com
US IR Adviser
Gilmartin Group
David Deuchler, CFA
Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden +44 (0)20 7886 2500
UK IR Adviser +44 (0)203 709 5700
Consilium Strategic Communications maxcyte@consilium-comms.com
Mary-Jane Elliott
Chris Welsh
About MaxCyte
MaxCyte is a leading commercial cell-engineering company focused
on providing enabling platform technologies to advance innovative
cell-based research as well as next-generation cell therapeutic
discovery, development and commercialization. Over the past 20
years, we have developed and commercialized our proprietary Flow
Electroporation(R) platform, which facilitates complex engineering
of a wide variety of cells. Our ExPERT(TM) platform, which is based
on our Flow Electroporation technology, has been designed to
support the rapidly expanding cell therapy market and can be
utilized across the continuum of the high-growth cell therapy
sector, from discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx(TM), STx(TM)
GTx(TM)and VLx(TM); a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by
a robust worldwide intellectual property portfolio.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BLRFFFVLFFITFIF
(END) Dow Jones Newswires
March 01, 2022 02:01 ET (07:01 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Sep 2023 to Sep 2024
